2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2549

Effect of Interleukin-6 Receptor Blockade on Proprotein Convertase Subtilisin/Kexin Type 9 Serum Levels in Rheumatoid Arthritis Patients
Abstract Number: 2550

Long Persistence of Anti-Drug Antibodies in Adalimumab Treated RA Patients
Abstract Number: 2551

Impact of Multmorbidity on Disability and Disease Activity over Time in Patients with RA Taking Biologics: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Abstract Number: 2552

Predictive Value of Chest HRCT Patterns for Respiratory Adverse Event Among RA Patients Treated with Biological Therapy: Long-Term Results from an Observational Study
Abstract Number: 2553

Pregnancy Outcomes in Patients with Rheumatoid Arthritis Treated with Abatacept – Review of a Safety Database
Abstract Number: 2554

Changes in Blood Pressure Following the Initiation of Disease Modifying Therapies in US Veterans with Rheumatoid Arthritis
Abstract Number: 2555

Efficacy and Safety of Conventional and Targeted Synthetic Disease-Modifying Antirheumatic Drugs As Well As Glucocorticoids: A Systematic Literature Review Informing the 2016 Update of the Eular Recommendations for the Management of Rheumatoid Arthritis
Abstract Number: 2556

Deficient Expression of the Novel Rheumatoid Arthritis (RA) Risk Gene, LBH, Induces S Phase Arrest in RA Fibroblast-like Synoviocytes (FLS)
Abstract Number: 2557

Tumor Necrosis Factor (TNF) Sensitizes Rheumatoid Synovial Fibroblasts to TRPA1-Mediated Calcium Flux, Anti-Proliferation and Cell Death
Abstract Number: 2558

Dissociation of the Inhibitory Apoptosis Stimulating Protein of p53 (iASPP) Binding with Transcription Factor p73 Induces Synovial Fibroblast Apoptosis in the Rheumatoid Joint
Abstract Number: 2559

Subgingival Microbiome Signatures in Patients with Established Rheumatoid Arthritis and Osteoarthritis
Abstract Number: 2560

Sputum Antibody to Malondialdehyde-Acetaldehyde Adduct in Subjects with Established Rheumatoid Arthritis
Abstract Number: 2561

A Novel Pharmacological Action of MTX on RA Fibroblast-like Synoviocytes Via Circadian Clock Genes
Abstract Number: 2562

Human Seroreactivity to Gut Microbiota Antigens in Rheumatoid Arthritis and Controls-Lack of Association with Rheumatoid Arthritis Autoantibodies
Abstract Number: 2563

Hypoxia Induce Slug Expression Via JAK/STAT3 Pathway in Rheumatoid Arthritis Fibroblast-like Synoviocytes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].